Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Moderate Buy” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned a consensus recommendation of “Moderate Buy” from the four analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $85.25.

Several research firms recently issued reports on PBH. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th.

Insider Activity at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William P’pool sold 8,987 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 over the last 90 days. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBH. OLD National Bancorp IN acquired a new stake in Prestige Consumer Healthcare during the second quarter worth approximately $262,000. QRG Capital Management Inc. boosted its stake in Prestige Consumer Healthcare by 4.7% in the second quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock valued at $372,000 after acquiring an additional 242 shares in the last quarter. ORG Partners LLC purchased a new position in shares of Prestige Consumer Healthcare during the second quarter worth about $39,000. Robbins Farley increased its position in shares of Prestige Consumer Healthcare by 7.7% during the second quarter. Robbins Farley now owns 31,480 shares of the company’s stock worth $2,167,000 after purchasing an additional 2,240 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Prestige Consumer Healthcare by 106.9% during the second quarter. Blue Trust Inc. now owns 867 shares of the company’s stock worth $63,000 after purchasing an additional 448 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Down 1.6 %

NYSE PBH opened at $82.26 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market capitalization of $4.06 billion, a P/E ratio of 20.02, a PEG ratio of 2.35 and a beta of 0.49. The firm’s 50-day moving average is $77.85 and its two-hundred day moving average is $72.35. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the company posted $1.07 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.